Pfizer reacts with a Press Release, rather than a warning about strokes and heart attacks.

Written by Michael Monheit, Esquire, Monheit Law, PC


Continued from page 1

The Food and Drug Administration plans to convene an advisory committee in February 2005 to reviewrepparttar cardiovascular safety of all COX-2 inhibitors. "We look forward to a scientific and reasoned evaluation in this appropriate setting," Dr. Feczko said.

Additional Information on Bextra

Bextra is contraindicated in patients who have demonstrated allergic-type reactions to sulfonamides; in patients with known hypersensitivity to valdecoxib; and in patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or NSAIDs because severe, rarely fatal, anaphylactic-like reactions to NSAIDS are possible in such patients. In rare cases, serious skin reactions can occur. Fatalities due to Stevens- Johnson syndrome and toxic epidermal necrolysis have been reported. If an allergic reaction is suspected or if there are other severe or unusual symptoms while taking Bextra, a patient should call his or her doctor or other healthcare professional immediately.

DISCLOSURE NOTICE: The information contained in this document is as of November 10, 2004. Pfizer assumes no obligation to update any forward-looking statements contained in this document as a result of new information or future events or developments.

This document contains forward-looking information. A list and description of risks and uncertainties relating to matters discussed in this document can be found inrepparttar 114637 Company's Annual Report on Form 10-K forrepparttar 114638 fiscal year ended December 31, 2003, and in its periodic reports on Forms 10-Q and 8-K.

(1) White WB, et al. "Effects ofrepparttar 114639 Cyclooxygenase-2 Specific Inhibitor Valdecoxib Versus Nonsteroidal Antiinflammatory Agents and Placebo on Cardiovascular Thrombotic Events in Patients with Arthritis." American Journal of Therapeutics. 2004; 11: 244-250. Number 4.



Michael Monheit, Esquire is the managing attorney for Monheit Law, located in Philadelphia, Pennsylvania Monheit Law, P.C. concentrates its practice in the field of plaintiff personal injury cases on a contingency fee basis. They can be found at http://www.monheit.com/Bextra


Medical Information about Bextra

Written by Michael Monheit, Esquire, Monheit Law, PC


Continued from page 1

Generalized Exfoliative Dermatitis is a severe inflammation ofrepparttar entire skin surface due to a reaction to certain drugs, or as a result of complications from another skin condition. In some cases, lymph node cancer (lymphoma) causes generalized exfoliative dermatitis.

Heart Attacks and Strokes A recent study (October/November 2004) showed that certain patients were at higher risk for heart attacks as a result of taking Bextra. An initial study last year raised similar concerns inrepparttar 114636 same kinds of patients. Coupling this withrepparttar 114637 information about Vioxx, anyone taking a Cox-2 inhibitor like Bextra should be concerned. Stevens Johnson Syndrome. Common causes arerepparttar 114638 drugs including Arava (leflunomide), painkillers, and antibiotics. Bextra has now been linked to this potentially life threatening syndrome. Symptoms of Stevens Johnson Syndrome are blistering, fever, cough, malaise, swelling and lesions of gums, tongue, or lips and excessive tearing or "stickiness" of eyes and sores inrepparttar 114639 genital tract causing painful urination.

Michael Monheit, Esquire is the managing attorney for Monheit Law, located in Philadelphia, Pennsylvania Monheit Law, P.C. concentrates its practice in the field of plaintiff personal injury cases on a contingency fee basis. They can be found at http://www.monheit.com/Bextra?Bextra-Lawyer


    <Back to Page 1
 
ImproveHomeLife.com © 2005
Terms of Use